Why the study?
Does dexmedetomidine infusion improve postoperative renal function in patients undergoing CABG surgery?
Does dexmedetomidine infusion improve postoperative renal function in patients undergoing CABG surgery?
Low-dose dexmedetomidine infusion does not significantly improve overall renal function after CABG surgery, though cumulative doses >110 mcg/day may offer early postoperative benefits in creatinine clearance.
Does not support dexmedetomidine for renal protection after CABG; leaves open a possible dose threshold for confirmation in larger RCTs.
Background: This study aims to investigate possible effects of dexmedetomidine on renal functions following coronary artery bypass graft (CABG) surgery. Methods: Between August 2008 and May 2009, consecutive 100 patients who underwent CABG surgery in our clinic were included in this double-blind and placebo-controlled study. Patients were randomized to either dexmedetomidine infusion or placebo. The sedation level of the patients was regulated using Ramsey Sedation Scale. Permuted blocks of four method was used to randomize patients. Results: A total of 86 patients were included in the analysis including 49 in the dexmedetomidine group and 37 in the placebo group. There was no statistically significant difference in major intraoperative and postoperative variables between the groups. Postoperative day 1 creatinine clearances values above cut-off point of 110 μg/day were significantly different between the groups. These changes were not observed in postoperative fifth day creatinine clearances values. Conclusion: Low dose dexmedetomidine has no major effect on urine output and renal indices such as urea, creatinine and creatinine clearances. However, it may have a positive effect on renal functions when total dose is uptitrated, particularly.
No takes yet. Share an insight, caveat, or question.
Deniz Göksedef (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: